FDA blocks Merck's OTC bid for Mevacor

12/13/2007 | Bloomberg1 · Wall Street Journal, The

An FDA advisory panel voted 10-2 to reject Merck & Co.'s third bid to obtain approval for an over-the-counter version of Mevacor. The panel was concerned that patients would not know how to use the cholesterol-lowering drug, which is now only available by prescription.

View Full Article in:

Bloomberg1 · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA